Skip to main content
. 2012;34(5):334–338. doi: 10.5581/1516-8484.20120088

Table 4.

Comparison between main outcomes by group (Non-intervention vs. Intervention Group): graft type, and conditioning regimen

  Non-intervention Group Intervention Group
  Graft type Conditioning regimen Graft type Conditioning regimen
  Related donor n = 57 Myeloablative n = 42 Nonablative n = 15 Related donor n = 25 Unrelated donor n = 9 Myeloablative n = 28 Nonablative n = 6
Hospital stay (days) - median (range) 43 (15-101) 43 (15-93) 41 (28-101) 41 (23-89) 48 (24-117) 42.5 (23-117) 36 (24-78)
Infections - n (%) 39 (68.4) 25 (59.5) 14 (93.3) 17 (68) 5 (55.5) 18 (64.3) 4 (6.66)
In-hospital deaths - n (%) 9 (15.8) 9 (15.8) 0 5 (20)   5 (55.5) 7 (25) 1 (16.6)
Death at 6 months - n (%) 14 (24.6) 12 (28.6) 2 (13.3) 8 (32) 3 (33.3) 10 (35.7) 1 (16.6)
Death at 12 months - n (%) 29 (50.9) 22 (52.4) 7 (4.6) 7 (28) 3 (33.3) 10 (35.7) 0
Number post-HSCT admissions - median (range) 2 (0-16) 2 (0-16) 2(0-15) 3 (1-14) 7 (0-14) 5 (1-14) 2.5 (0-12)
Chronic GVHD - n (%)              
    None 34 (59.65) 29 (69) 5 (33.3) 20 (80) 9 (100) 24 (85.7) 5 (83.3)
    Limited 13 (22.8) 8 (19) 5 (33.3) 4 (16) 0 4 (14.3) 0
    Extensive 10 (17.5) 5 (11.9) 5 (33.3) 1 (4) 0 0 1 (16.6)
Acute GVHD - n (%)              
    Grade I/II 14 (24.6) 8 (19) 6 (40) 9 (36) 3 (33.3) 10 (35.7) 2 (33.3)
    Grade III/IV 10 (17.5) 7 (16.6) 3 (20) 3 (12) 1 (11.1) 3 (10.7) 1 (16.6)
CMV - n (%) 10 (17.5) 8 (19) 2 (13.3) 7 (28) 4 (44.4) 8 (28.6) 3 (50)
In-hospital weight loss > 10% - n (%) 22 (38.6) 14 (33.3) 8 (53.3) 10 (40) 5 (55.5) 12 42.8) 3 (50)
Neutropenia - n (%) 55 (96.5) 41 (97.6) 14 (93.3) 20 (80) 8 (88.8) 22 (78.5) 6 (100)

HSCT: Hematopoietic stem cell transplantation; GVHD: Graft versus host disease; CMV: Cytomegalovirus